Understanding how medicinal cannabis is prescribed, regulated and dispensed within Australia's healthcare system.
Australia has established a regulatory framework that allows eligible patients to access medicinal cannabis through appropriate healthcare pathways.
However, understanding the process can be challenging, particularly because different rules may apply depending on the medicine, the prescribing practitioner and the patient's circumstances.
This article explains the general process for accessing medicinal cannabis in Australia, including the role of healthcare professionals, the Therapeutic Goods Administration (TGA), pharmacies and the relevant regulatory pathways.
Medicinal cannabis can be legally prescribed and supplied throughout Australia when the applicable regulatory requirements are met.
Cannabis-based medicines are regulated as therapeutic goods and may also be subject to controlled-drug requirements.
Some medicinal cannabis products are registered on the Australian Register of Therapeutic Goods (ARTG).
Many other products supplied in Australia are unapproved therapeutic goods, meaning they have not undergone the TGA's full assessment for registration.
Unapproved products may be accessed through specific regulatory pathways when the relevant requirements are satisfied.
There is no single national list of medical conditions that automatically qualifies a person for medicinal cannabis treatment.
A healthcare professional must assess the individual patient's circumstances, including:
Medical history and current symptoms
Existing diagnoses and previous treatments
Current medicines and potential interactions
Available clinical evidence
Possible adverse effects and safety concerns
Relevant regulatory and prescribing requirements
Medicinal cannabis is not suitable for everyone.
The decision to prescribe any medicine must be based on appropriate clinical judgment and applicable professional obligations.
Healthcare practitioners play a central role in the lawful prescribing of medicinal cannabis.
An assessment may involve reviewing a patient's medical history, previous treatment experiences, current medications and relevant clinical information.
The practitioner must determine whether a particular treatment is clinically appropriate and whether the legal requirements for prescribing can be satisfied.
Depending on the medicine and regulatory pathway, additional approvals or authorisations may be required.
A consultation does not guarantee that a prescription will be issued.
The process varies depending on the medicine and circumstances, but generally involves the following stages.
The patient consults an appropriately qualified healthcare practitioner.
The practitioner assesses the patient's medical circumstances and discusses relevant treatment options, potential risks and available evidence.
If a medicine is registered on the ARTG, it may be prescribed in accordance with applicable prescribing requirements.
For an unapproved medicinal cannabis product, an appropriate regulatory pathway may be required.
Two important pathways are the Special Access Scheme and Authorised Prescriber Scheme.
Where prescribing is clinically appropriate and the relevant regulatory requirements are met, the practitioner may issue a prescription.
The prescription must comply with applicable Commonwealth, state and territory requirements.
A pharmacist reviews and dispenses the prescription in accordance with relevant medicines legislation and professional obligations.
The pharmacist may provide information about the prescribed medicine, its administration, storage and relevant precautions.
As with other prescription medicines, follow-up may be required to assess treatment outcomes, adverse effects and whether continued treatment is appropriate.
The frequency and nature of reviews depend on the patient's circumstances and the prescribing practitioner's clinical judgment.
The TGA's Special Access Scheme provides mechanisms through which eligible healthcare practitioners may arrange access to unapproved therapeutic goods for individual patients.
Different categories apply depending on the circumstances.
Under SAS Category B, an application generally requires TGA approval before supply.
Other access arrangements, including SAS Category A for eligible patients, operate under different requirements.
The applicable pathway depends on the medicine, patient and relevant regulatory criteria.
The Authorised Prescriber Scheme allows eligible medical practitioners to prescribe specified unapproved therapeutic goods to particular patient groups under an applicable authorisation.
Once appropriately authorised, a practitioner may prescribe within the scope and conditions of that authorisation without submitting an individual SAS Category B application for each patient.
Authorised Prescribers remain subject to relevant reporting, prescribing and professional requirements.
Telehealth allows healthcare consultations to take place remotely using telephone or video communication.
In some circumstances, telehealth may be suitable for a clinical assessment involving medicinal cannabis.
However, the appropriateness of telehealth depends on the patient's needs, the practitioner's professional obligations and applicable prescribing requirements.
An in-person consultation or further clinical assessment may be necessary.
Telehealth does not remove the legal requirements associated with prescribing controlled medicines.
Medicinal cannabis is supplied through regulated medicines distribution and pharmacy dispensing arrangements.
Depending on the circumstances, a prescription may be dispensed by an appropriately authorised pharmacy.
Pharmacies must comply with applicable requirements relating to controlled medicines, storage, recordkeeping and supply.
Collection or delivery arrangements depend on the pharmacy, the medicine and relevant legal requirements.
Patients should follow the instructions provided by their healthcare practitioner and dispensing pharmacist.
Important considerations include:
Clinical evidence
The evidence supporting medicinal cannabis varies between conditions and formulations.
Potential adverse effects
Cannabinoid-based medicines may cause dizziness, drowsiness, cognitive impairment, gastrointestinal effects and other adverse reactions.
Medicine interactions
Cannabinoids can interact with other medicines. A complete medication history is important.
Driving
THC-containing medicines can impair driving, and a prescription does not necessarily provide an exemption from Australian drug-driving laws.
Cost
Many medicinal cannabis products are not subsidised through the Pharmaceutical Benefits Scheme. Costs may vary.
Ongoing review
Clinical monitoring helps assess treatment outcomes, adverse effects and continued suitability.
The Therapeutic Goods Administration provides official information about medicinal cannabis regulation, access pathways and safety considerations.
Patients can also seek advice from their treating healthcare practitioner or pharmacist.
Information from commercial websites should be assessed carefully, particularly where it includes promotional claims about prescription medicines.
Australia has established pathways through which medicinal cannabis may be prescribed and supplied under appropriate clinical and regulatory supervision.
The process involves healthcare assessment, applicable regulatory requirements, lawful prescribing and pharmacy dispensing.
Understanding these stages can help patients engage in informed discussions with their healthcare professionals.
Medicinal cannabis is not appropriate for everyone, and access to a particular product is not guaranteed.
Important information
This article is provided for general educational purposes only. It does not constitute medical advice, recommend medicinal cannabis for any particular condition or guarantee access to prescription medicines. Patients should consult an appropriately qualified healthcare professional regarding their individual circumstances.